The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J05 | Antivirals for systemic use | |
3
|
J05A | Direct acting antivirals | |
4
|
J05AR | Antivirals for treatment of HIV infections, combinations | |
5
|
J05AR01 | Zidovudine and lamivudine |
| Active Ingredient |
|---|
|
Lamivudine and zidovudine are nucleoside analogues which have activity against HIV. Additionally, lamivudine has activity against hepatitis B virus (HBV). Both medicinal products are metabolised intracellularly to their active moieties, lamivudine 5'-triphosphate (TP) and zidovudine 5'-TP respectively. Their main modes of action are as chain terminators of viral reverse transcription. |
| Document | Type | Information Source | |
|---|---|---|---|
| COMBIVIR Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.